Develop a Novel Monoclonal Antibody for the Therapy of Rheumatoid Arthritis
研發一種新型單株抗體以治療風濕性關節炎
BR mAb is a monoclonal antibody generated using a peptide fragment (BR Ag) from Porphyromonas gingivalis, showing strong affinity and specificity towards BR Ag. While traditional therapies target inflammation by selectively blocking TNF, BR mAb offers a new treatment option for rheumatoid arthritis.
BR mAb 是由牙齦卟啉單孢菌的胜肽片段 (BR Ag) 生成的單株抗體，其與 BR Ag 的親和力強，且對 BR Ag 具有特異性反應。傳統治療通常針對特異性阻斷 TNF 以處理發炎。然而，BR mAb 在治療類風濕性關節炎方面提供了一種新的選擇。
Targeted indication
Rheumatoid arthritis
Status
Pre-clinical studies
Key features
- Anti-BR Ag-like antibody
Market
The global rheumatoid arthritis market size was US$57.93 billion in 2019 and is expected to reach US$62.94 billion in 2027 (CAGR of 2.8%).
MODE OF ACTION
The BR mAb inhibits inflammatory responses by targeting synovial cells expressing BR Ag-like Ag.
EXPERIMENTAL RESULTS
INTELLECTUAL PROPERTY
SELECTED PUBLICATIONS
Not yet published
BUSINESS OPPORTUNITY
Rheumatoid arthritis affects 1% of the population, and clinical diagnosis followed by treatment with biologics effectively alleviates pain and disease progression. However, 30% of patients show inadequate response to treatment. We propose an alternative therapeutic approach targeting not only anti-BR Ag-positive rheumatoid arthritis patients but also those who do not respond to biologic therapy.
CONTACT
service@biip-dcc.org